MedTrace Logo

Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C

NCT02526641 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2020-11-04

No results posted yet for this study

Summary

Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the hepatic venous pressure gradient (HVPG), and metabolic liver function determined by the galactose elimination capacity (GEC) test and the functional hepatic nitrogen clearance (FHNC).

Conditions

  • Hepatitis C

Interventions

PROCEDURE

Functional Hepatic Nitrogen Clearance (FHNC)

PROCEDURE

Galactose Elimination Capacity (GEC)

PROCEDURE

Liver vein catheterization

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • AbbVie

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Grønbæk, Professor · Aarhus University Hospital

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2019-03-31
Completion
2020-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526641 on ClinicalTrials.gov